FDA Agrees To Pivotal Protocol For Oxigene’s Vascular Disrupting Agent Zybrestat
Oxigene has begun enrollment in the Phase II/III trial to test combretastatin-A4 in the orphan setting of anaplastic thyroid cancer.
Oxigene has begun enrollment in the Phase II/III trial to test combretastatin-A4 in the orphan setting of anaplastic thyroid cancer.